XML 64 R34.htm IDEA: XBRL DOCUMENT
v3.25.3

ACQUISITIONS (Tables) | 12 Months Ended
--- | ---
Aug. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] |
Schedule of Business Combination, Recognized Asset Acquired and Liability Assumed | The following table summarizes the allocation of the final purchase price for Immunetrics:
(in thousands) |  |
Base merger consideration |  | $ | 12,000 |
Fair value of earnout |  | 4,100 |
Cash on hand |  | 1,247 |
Adjustment to purchase price for closing indebtedness |  | (122) |
Net working capital adjustment |  | (377) |
D&O tail insurance |  | (7) |
Bonus compensation to Immunetrics staff |  | (1,586) |
Total purchase price |  | 15,255 |
Fair value of identifiable assets acquired: |  |
Cash |  | 1,132 |
Accounts receivable |  | 511 |
Security deposit |  | 12 |
ROU asset |  | 227 |
Deferred tax assets |  | 799 |
Trade names |  | 1,800 |
Customer relationships |  | 3,780 |
Developed Tech |  | 1,080 |
Non-competes |  | 30 |
|  | 9,371 |
Fair value of liabilities assumed: |  |
Lease liability |  | 227 |
Selling shareholders' D&O tail insurance responsibility |  | 7 |
Deferred revenue |  | 60 |
|  | 294 |
Fair value of identifiable assets acquired and liabilities assumed |  | 9,077 |
Goodwill |  | $ | 6,178 |
The following table summarizes the allocation of the final purchase price for Pro-ficiency:
(in thousands) |  | Estimated fair value as previously reported (a) |  | Measurement Period Adjustments |  | Fair Value as adjusted
Base merger consideration |  | $ | 100,000 |  |  | $ | — |  |  | $ | 100,000 |
Net working capital adjustment |  | (85) |  |  | — |  |  | (85) |
Excess cash adjustment |  | 1,731 |  |  | 227 |  |  | 1,958 |
Adjustment to purchase price for closing indebtedness |  | (1,484) |  |  | — |  |  | (1,484) |
Total purchase price |  | 100,162 |  |  | 227 |  |  | 100,389 |
Fair value of identifiable assets acquired: |  |  |  |  |  |
Cash |  | 2,513 |  |  | — |  |  | 2,513 |
Accounts receivable |  | 2,064 |  |  | — |  |  | 2,064 |
Prepaids and other current assets |  | 1,807 |  |  | — |  |  | 1,807 |
ROU asset |  | 212 |  |  | — |  |  | 212 |
Trade names |  | 8,400 |  |  | — |  |  | 8,400 |
Customer relationships |  | 2,310 |  |  | — |  |  | 2,310 |
Developed technology |  | 16,630 |  |  | — |  |  | 16,630 |
Non-competes |  | 70 |  |  | — |  |  | 70 |
Other non-current assets |  | 17 |  |  | — |  |  | 17 |
|  | 34,023 |  |  | — |  |  | 34,023 |
Fair value of liabilities assumed: |  |  |  |  |  | — |
Accounts payable |  | 935 |  |  | — |  |  | 935 |
Payroll and other current liabilities |  | 2,302 |  |  | — |  |  | 2,302 |
Deferred revenue |  | 1,456 |  |  | — |  |  | 1,456 |
Lease liability |  | 212 |  |  | — |  |  | 212 |
Deferred tax liabilities |  | 4,811 |  |  | (956) |  |  | 3,855 |
Other liabilities |  | 1,124 |  |  | — |  |  | 1,124 |
|  | 10,840 |  |  | (956) |  |  | 9,884 |
Fair value of identifiable assets acquired and liabilities assumed |  | 23,183 |  |  |  |  | 24,139 |
Goodwill |  | $ | 76,979 |  |  |  |  | $ | 76,250 |
(a) As previously reported in the Company's Annual Report on Form 10-K for the year ended August 31, 2024.
Schedule of Business Combination, Intangible Asset, Acquired, Finite-Lived and Indefinite-Lived | The following table summarizes intellectual property as of August 31, 2025:
(in thousands) |  | Amortization Period |  | Acquisition Value |  | Accumulated Amortization |  | Impairment |  | Net Book Value
Developed technologies–DILIsym acquisition |  | Straight line 9 years |  | $ | 2,850 |  |  | $ | 2,610 |  |  | $ | — |  |  | $ | 240 |
Intellectual rights of Entelos Holding Company |  | Straight line 10 years |  | 50 |  |  | 36 |  |  | — |  |  | 14 |
Developed technologies–Lixoft acquisition |  | Straight line 16 years |  | 8,010 |  |  | 2,670 |  |  | — |  |  | 5,340 |
Developed technologies–Immunetrics acquisition |  | Straight line 5 years |  | 1,080 |  |  | 477 |  |  | — |  |  | 603 |
Developed technologies–Pro-ficiency acquisition |  | Straight line 5 years |  | 16,630 |  |  | 3,228 |  |  | 13,402 |  |  | — |
|  |  |  | $ | 28,620 |  |  | $ | 9,021 |  |  | $ | 13,402 |  |  | $ | 6,197 |
In connection with the identified triggering event as of May 31, 2025, the Company performed, prior to the goodwill impairment test, a quantitative assessment of its long-lived assets and concluded that its long-lived assets were impaired at certain reporting units. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Developed technologies related to the Pro-ficiency acquisition were determined to be impaired. Such charges of $13.4 million are recorded in impairments on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The following table summarizes intellectual property as of August 31, 2024:
(in thousands) |  | Amortization Period |  | Acquisition Value |  | Accumulated Amortization |  | Net Book Value
Developed technologies–DILIsym acquisition |  | Straight line 9 years |  | $ | 2,850 |  |  | $ | 2,294 |  |  | $ | 556 |
Intellectual rights of Entelos Holding Company |  | Straight line 10 years |  | 50 |  |  | 30 |  |  | 20 |
Developed technologies–Lixoft acquisition |  | Straight line 16 years |  | 8,010 |  |  | 2,173 |  |  | 5,837 |
Developed technologies–Immunetrics acquisition |  | Straight line 5 years |  | 1,080 |  |  | 261 |  |  | 819 |
Developed technologies–Pro-ficiency acquisition |  | Straight line 5 years |  | 16,630 |  |  | 732 |  |  | 15,898 |
|  |  |  | $ | 28,620 |  |  | $ | 5,490 |  |  | $ | 23,130 |
The following table presents the details of intangible assets acquired.
(in thousands) |  | Estimated useful life |  | Amount
Indefinite-lived: |  |  |  |
Trade names |  | Indefinite |  | $ | 1,800 |
Definite-lived: |  |  |  |
Customer relationships |  | 9 years |  | 3,780 |
Developed technologies |  | 5 years |  | 1,080 |
Covenants not to compete |  | 2 years |  | 30 |
Total definite-lived intangible assets |  |  |  | 4,890 |
Total intangible assets |  |  |  | $ | 6,690 |
The following table presents the details of intangible assets acquired.
|  | Estimated useful life |  | Amount
Indefinite-lived: |  |  |  |
Trade names |  | Indefinite |  | $ | 8,400 |
Definite-lived: |  |  |  |
Customer relationships |  | 10 years |  | 2,310 |
Developed technologies |  | 5 years |  | 16,630 |
Non-competes |  | 3 years |  | 70 |
Total definite-lived intangible assets |  |  |  | 19,010 |
Total intangible assets |  |  |  | $ | 27,410 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | The estimated future amortization of finite-lived intangible assets for the next five years is as follows:
(in thousands) |  | Amount
Years ending August 31, |
2026 |  | $ | 3,580 |
2027 |  | $ | 3,580 |
2028 |  | $ | 3,580 |
2029 |  | $ | 3,557 |
2030 |  | $ | 3,557 |
Schedule of Business Combination, Pro Forma Information |
|  | (Pro forma) 2024 * |  | (Pro forma) 2023 |  |
(in thousands) |  | (unaudited) |  | (unaudited) |  |
Revenue |  | $ | 83,243 |  |  | $ | 76,892 |  |  |
Net (loss) income |  | $ | 7,790 |  |  | $ | 4,547 |  |  |
* Balances include actual results from acquisition date of June 16, 2023 through August 31, 2023 for Immunetrics and from acquisition date of June 11, 2024 through August 31, 2024 for Pro-ficiency business.

X
- Definition Tabular disclosure of pro forma revenue and earnings for business combination or aggregate of series of individually immaterial business combinations. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-49 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired in business combination. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 40 -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration